Corcept Therapeutics Incorporated (CORT) Shareholders & Insider Trades
Corcept Therapeutics shareholders at a glance
The largest holder of Corcept Therapeutics stock is BlackRock Advisors LLC, with 11.9 million shares (10.98% of the company), worth about $1.35 billion as of September 25, 2026. The 10 largest holders together own 49.3%.
In Q2 2026, 453 institutional holdings reports listed 92.0 million shares worth $7.27 billion, up 15.6% in shares from Q1 2026.
Insiders reported 50 transactions in the last two years: 24 sales worth $29.36 million and no purchases. The newest one on file is from November 5, 2025 (Guyer William, Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through November 5, 2025.
Corcept Therapeutics Incorporated
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Corcept Therapeutics shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Advisors LLC | 11.9 million | 10.98% | $1.3B |
| Ingalls & Snyder LLC | 7.9 million | 7.34% | $899.0M |
| George Baker5.134 % | 5.6 million | 5.13% | $629.0M |
| Renaissance Technologies LLC | 5.3 million | 4.87% | $596.0M |
| Vanguard Portfolio Management LLC | 5.0 million | 4.67% | $572.0M |
| Vanguard Capital Management LLC | 4.2 million | 3.86% | $473.0M |
| Parallel Advisors LLC | 4.0 million | 3.67% | $449.0M |
| Fidelity Management & Research Co. LLC | 3.3 million | 3.09% | $378.0M |
| State Street Corporation | 3.3 million | 3.03% | $372.0M |
| Joseph Belanoff2.651 % | 2.9 million | 2.65% | $325.0M |
As of September 25, 2026.
Corcept Therapeutics institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 453 | 92.0 million | $7.3B |
| Q1 2026 | 372 | 79.6 million | $3.2B |
| Q4 2025 | 426 | 76.9 million | $2.7B |
| Q3 2025 | 460 | 78.0 million | $6.5B |
| Q2 2025 | 455 | 79.7 million | $5.9B |
| Q1 2025 | 466 | 83.4 million | $9.3B |
| Q4 2024 | 401 | 84.4 million | $4.3B |
| Q3 2024 | 347 | 88.8 million | $4.1B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Corcept Therapeutics insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Guyer William | Nov 5, 2025 | Officer | Sale at price 74.75 - 76.28 per share. | $1.5M |
| Belanoff Joseph K | Nov 5, 2025 | Chief Executive Officer | Sale at price 74.08 - 75.98 per share. | $3.0M |
| Guyer William | Nov 5, 2025 | Officer | Conversion of Exercise of derivative security at price 21.65 per share. | $433,000 |
| Lyon Joseph Douglas | Nov 3, 2025 | Chief Technology Officer | Sale at price 73.65 per share. | $368,244 |
| Maduck Sean | Nov 3, 2025 | Officer | Sale at price 73.99 per share. | $1.5M |
| Maduck Sean | Nov 3, 2025 | Officer | Conversion of Exercise of derivative security at price 8.27 per share. | $165,400 |
| Lyon Joseph Douglas | Nov 3, 2025 | Chief Technology Officer | Conversion of Exercise of derivative security at price 13.56 per share. | $67,800 |
| Swisher Daniel N Jr | Oct 10, 2025 | Director | Sale at price 87.54 per share. | $192,588 |
| Swisher Daniel N Jr | Oct 10, 2025 | Director | Conversion of Exercise of derivative security at price 14.08 per share. | $30,976 |
| Guyer William | Oct 7, 2025 | Officer | Sale at price 89.94 per share. | $1.8M |
| Guyer William | Oct 7, 2025 | Officer | Conversion of Exercise of derivative security at price 21.65 per share. | $433,000 |
| Lyon Joseph Douglas | Oct 1, 2025 | Chief Technology Officer | Sale at price 83.71 - 85.39 per share. | $423,766 |
Newest 12 of 50 insider transactions in the last two years.
Questions and answers
Who owns the most Corcept Therapeutics stock?
BlackRock Advisors LLC, with 10.98% of the company (as of September 25, 2026). Next: Ingalls & Snyder LLC (7.34%) and George Baker5.134 % (5.13%).
How many institutions own Corcept Therapeutics stock?
453 institutional holdings reports listed Corcept Therapeutics shares in Q2 2026, 92.0 million shares in all worth $7.27 billion.
Are Corcept Therapeutics insiders buying or selling the stock?
In the last two years insiders reported 24 sales and no purchases (50 transactions in all); the newest on file is from November 5, 2025.
